SHAREHOLDER ALERT: EHTH ELMS FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / March 11, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

eHealth, Inc. EHTH

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ehealth-inc-loss-submission-form?prid=24610&wire=1
Lead Plaintiff Deadline: March 18, 2022
Class Period: April 26, 2018 - July 23, 2020

The complaint alleges, in part, that: 1) statements made by defendants gave investors the false impression that the commission receivables reported by eHealth had no associated costs; and 2) the Company failed to disclose that eHealth in fact had additional operating expenses that it must incur in order to retain customers and keep them from cancelling their policies within the first year. These costs included the cost of providing "customer care service," and these operating costs had to be offset against any commissions receivable.

Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corp. ELMS

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/electric-last-mile-solutions-inc-f-k-a-forum-merger-iii-corp-loss-submission-form?prid=24610&wire=1
Lead Plaintiff Deadline: April 4, 2022
Class Period: March 31, 2021 - February 1, 2022

Allegations against ELMS include that: (1) ELMS's previously issued financial statements were false and unreliable; (2) ELMS's earlier reported financial statements would need restatement; (3) certain ELMS executives and/or directors purchased equity in the Company at substantial discounts to market value without obtaining an independent valuation; (4) on November 25, 2021 (Thanksgiving), the Company's Board formed an independent Special Committee to conduct an inquiry into certain sales of equity securities made by and to individuals associated with the Company; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Fennec Pharmaceuticals Inc. FENC

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?prid=24610&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: May 28, 2021 - November 26, 2021

Allegations against FENC include that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE : The Law Offices of Vincent Wong